EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Tuesday, October 22nd 2019 at 1:00pm UTC SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round. The funding will be used to invest in both …
Plus »SkyKnight Capital Invests in Home Healthcare Leader AeroCare
Monday, October 21st 2019 at 12:00pm UTC SAN FRANCISCO–(BUSINESS WIRE)– SkyKnight Capital (“SkyKnight”), a San Francisco based private equity firm, announced that it has made an investment into AeroCare Holdings, Inc. (“AeroCare” or the “Company”), a leading provider of home healthcare solutions focused on patients with chronic respiratory conditions. AeroCare …
Plus »Venarum Medical Receives Ongoing NIH SBIR Grant Support for its EndoVenous Valve System Development
Monday, October 21st 2019 at 7:44pm UTC Ongoing NIH SBIR Support Enables Progress Towards a Prosthetic Venous Valve EATONTOWN, N.J.–(BUSINESS WIRE)– Venarum Medical, LLC today announced receipt of a mentorship grant in further support of its awarded Phase II SBIR Grant “EVVS: EndoVenous Valve System” currently underway. Under its Phase …
Plus »XLerateHealth Receives NIH Funding to Continue Development of Healthcare Innovation in Under-Resourced States
Monday, October 21st 2019 at 12:00pm UTC Grants total over $1.7M for 2nd Year of XLerator Network; Funds will support academic healthcare innovation across the Southeast LOUISVILLE, Ky.–(BUSINESS WIRE)– XLerateHealth (XLH) is pleased to announce that it was awarded Phase II funding of $1.48M, plus an Administrative Supplement of $250,000, …
Plus »Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board
Monday, October 21st 2019 at 4:05am UTC PSGL-1 identified as lead macrophage checkpoint modulator (MCM) program for development in cancer BEDFORD, Mass.–(BUSINESS WIRE)– Verseau Therapeutics, Inc. (“Verseau”) launched today with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation …
Plus »Syngenta Commits $2 Billion and Sets New Targets for Innovation to Tackle Climate Change
Tuesday, October 22nd 2019 at 6:00am UTC BASEL, Switzerland–(BUSINESS WIRE)– Syngenta: Syngenta dedicates $2 billion over five years to innovation specifically targeted at delivering a step change in agricultural sustainability CEO Erik Fyrwald will explain new goal to drive two technological breakthroughs to market each year at Sustainability Summit …
Plus »Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Friday, October 18th 2019 at 10:59am UTC NEW YORK–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to exchange (the “Exchange Offers”) notes (the “Celgene Notes”) issued by Celgene Corporation (NASDAQ:CELG) (“Celgene”) for up to $19,850,000,000 aggregate principal amount of …
Plus »ArsenalBio Launches With $85 Million Series A Financing to Advance New Paradigm to Discover and Develop Immune Cell Therapies
Thursday, October 17th 2019 at 11:00am UTC — Aims to create immune cells with significantly larger DNA payloads encoding synthetic biological instructions to overcome solid tumors’ complex defense systems — — Aspires to evolve critical success metrics of immune cell therapies – efficacy, safety, cost, and access – with programmable, …
Plus »Healx Secures $56M in Series B Financing, Launches Global Accelerator Programme for Rare Diseases
Wednesday, October 16th 2019 at 7:00am UTC Latest round of funding, led by Atomico, will be used to build a clinical-stage portfolio for rare diseases, including treatments for fragile X syndrome, the leading genetic cause of autism Healx’s Rare Treatment Accelerator programme is a new initiative launched in close partnership …
Plus »Amarna Therapeutics Raises €10 million to Progress lead Development Candidate into Clinical Trials and Appoints a new Supervisory Board
Wednesday, October 16th 2019 at 3:04pm UTC Round led by Swedish investor Flerie Invest AB with substantial contributions from the Netherlands Enterprise Agency and existing shareholders Appoints a new Supervisory Board with six highly experienced individuals Start of first-in-man phase I/II clinical study of its SV40-based gene delivery vector platform …
Plus »
